Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (495)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03033303 | A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma | completed | Phase 2 | 59 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT06439420 | CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial(CBT-I in PBT) | completed | Phase 2 | 70 | Virginia Commonwealth UniversityOTHER | 1 | Oct 1, 2025 |
| clinicaltrials |
| NCT05608395 | 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)(GlioMET) | completed | Phase 2 | 33 | Masaryk Memorial Cancer InstituteOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT03050736 | Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression | completed | Phase 2 | 29 | Kintara Therapeutics, Inc.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT01478178 | Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 55 | Kintara Therapeutics, Inc.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT02717962 | Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting | completed | Phase 2 | 118 | Kintara Therapeutics, Inc.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT02327078 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | completed | Phase 1 / Phase 2 | 307 | Incyte CorporationINDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT07120620 | PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed Glioblastoma(PriCoTTF) | completed | Phase 1 / Phase 2 | 33 | Sied KebirOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT04388475 | Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma | completed | Phase 2 | 57 | Oblato, Inc.INDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT01931098 | Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05012098 | Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2025 | clinicaltrials |
| NCT01295944 | Carboplatin and Bevacizumab for Recurrent Ependymoma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2025 | clinicaltrials |
| NCT03137888 | Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma | completed | Phase 2 | 30 | Emory UniversityOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT02986178 | Lerapolturev in Recurrent Malignant Glioma | completed | Phase 2 | 121 | Istari Oncology, Inc.INDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT00703222 | A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells(CHESAT) | completed | Phase 1 / Phase 2 | 7 | Baylor College of MedicineOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT02781792 | Temozolomide Chronotherapy for High Grade Glioma | completed | Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | completed | Phase 2 | 267 | Epizyme, Inc.INDUSTRY | 9 | Jun 22, 2025 | clinicaltrials |
| NCT04740190 | Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd(TAC-GReD) | completed | Phase 2 | 33 | The University of Hong KongOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT02655601 | Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001(BMX-HGG) | completed | Phase 1 / Phase 2 | 177 | BioMimetix JV, LLCINDUSTRY | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04051606 | Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT04479241 | LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma | completed | Phase 2 | 25 | Istari Oncology, Inc.INDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT02311582 | MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 55 | Washington University School of MedicineOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT03047473 | Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme(SEJ) | completed | Phase 2 | 38 | Clinique Neuro-OutaouaisOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT03782415 | Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 64 | MediciNovaINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT03665545 | Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma(IMA950-106) | completed | Phase 1 / Phase 2 | 18 | University Hospital, GenevaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05289908 | Intrathecal Pemetrexed for Leptomeningeal Metastasis | completed | Phase 1 / Phase 2 | 34 | The First Hospital of Jilin UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT02715609 | Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 35 | Washington University School of MedicineOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT03522298 | Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma | completed | Phase 2 | 30 | Kazia Therapeutics LimitedINDUSTRY | 1 | Mar 24, 2025 | clinicaltrials |
| NCT03770416 | Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma | completed | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT01894061 | NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma | completed | Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03213691 | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 2 | Feb 5, 2025 | clinicaltrials |
| NCT02078648 | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 74 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT03495960 | Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System(FIORELLA) | completed | Phase 2 | 72 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 4 | Jan 30, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT02960230 | H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | completed | Phase 1 / Phase 2 | 50 | Sabine Mueller, MD, PhDOTHER | 2 | Jan 22, 2025 | clinicaltrials |
| NCT02465268 | Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme(ATTAC-II) | completed | Phase 2 | 175 | University of FloridaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03914742 | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations | completed | Phase 1 / Phase 2 | 67 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04280848 | Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma(UCPVax-Glio) | completed | Phase 2 | 67 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04841434 | A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL(VALIDATE) | completed | Phase 1 / Phase 2 | 18 | Charite University, Berlin, GermanyOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01464177 | Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme(GBM Hypo RT) | completed | Phase 2 | 40 | Andre Tsin Chih ChenOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03732352 | 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma | completed | Phase 2 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04845919 | Sonodynamic Therapy With ExAblate System in Glioblastoma Patients(Sonic ALA) | completed | Phase 2 | 5 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT01149850 | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03234595 | A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma | completed | Phase 1 / Phase 2 | 22 | Everfront Biotech Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03661723 | Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Oct 7, 2025source: clinicaltrials